Patisiran is a small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is available as lipid complex injection for intravenous use. MedsAcross supplies Patisiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ONPATTRO contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Source: US FDA prescribing information
Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Source: US FDA prescribing information
For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg every 3 weeks by intravenous infusion. For patients weighing 100 kg or more, the recommended dosage is 30 mg. Premedicate with a corticosteroid, acetaminophen, and antihistamines. Filter and dilute prior to administration. Infuse over approximately 80 minutes
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Infusion-related reactions: Monitor for signs and symptoms during infusion. Slow or interrupt the infusion if clinically indicated. Discontinue the infusion if a serious or life-threatening infusion-related reaction occurs. Reduced serum vitamin A levels and recommended supplementation: Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion-Related Reactions The most frequently reported adverse reactions (that occurred in at least 10% of ONPATTRO-treated patients and at least 3% more frequently than on placebo) were upper respiratory tract infections and infusion-related reactions
Source: US FDA prescribing information
Store at 2°C to 8°C (36°F to 46°F). Do not freeze. If refrigeration is not available, ONPATTRO can be stored at room temperature up to 25°C (up to 77°F) for up to 14 days. For storage conditions of ONPATTRO after dilution in the infusion bag, see Dosage and Administration.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Patisiran, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Onpattro 10 mg/5 mL lipid complex injectionIntravenous Cold chain | Alnylam Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Patisiran in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Patisiran and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Patisiran, including Onpattro.
Yes. The US FDA first approved Patisiran on 10 August 2018, according to Drugs@FDA.
Yes. Patisiran has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Patisiran must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Patisiran is classified under ATC code N07XX12 (Patisiran).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.